Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com
MicroCapSpeculators.com News Commentary
LAS VEGAS, October 5, 2017 /PRNewswire/ --
If you know anything about the biotechnology field you know that the potential of a start-up company is enormous. But with this enormous potential, comes massive risks with product development. One of the most important strategies in determining whether or not a biotechnology company will be successful is tracking their pre-clinical studies during product development. The pre-clinical development process encompasses the activities that connect drug discovery in the laboratory to initiation of human clinical trials. Usually, the drug development process is separated into three steps: discovery, pre-clinical development, and clinical trial. What makes the pre-clinical stage so important, is it determines whether the drug will go into clinical trials with humans. A few biotechnology companies who should be on your watch list and are in the pre-clinical stage of immunotherapy drug development include: Endonovo Therapeutics (OTC: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), NewLink Genetics Corporation (NASDAQ: NLNK), and Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Vical Incorporated (NASDAQ: VICL).
Endonovo Therapeutics (OTCQB: ENDV)
Market Cap: $19.4M, current share price: $.0715
ENDV is at the top of this list as they are the most promising and performing the best right now in their pre-clinical trials testing their Immunotronic therapies, which use electrical stimulation to suppress an out of control immune response to injuries and disease. They announced just this week that interim results from their ongoing pre-clinical study assessing the effectiveness of its Immunotronics™ platform in the treatment and prevention of heart failure following myocardial infarction demonstrated improved cardiac function and less ventricular remodeling. This was evaluated by echocardiography in infarcted animals treated with the Company's non-invasive electroceutical two or three times per day for four weeks when compared to the control group. The Company expects final results to come out in the next few weeks. Additionally, they're preparing to conduct further pre-clinical studies using its newly developed electroceutical technology in the treatment of critical limb ischemia, kidney disease and Non-Alcoholic Steatohepatitis (NASH).
Pulse Biosciences, Inc. (NASDAQ: PLSE)
Market Cap: $264.044M, current share price: $18.62
PLSE is a medical technology company developing a therapeutic tissue treatment platform based on Nano-Pulse Stimulation, a proprietary cell signaling technology similar to the technology ENDV. PLSE announced treatment of the first patient in the Company's multi-center study evaluating the safety and efficacy of the NPS technology for the treatment of seborrheic keratosis (SK). The study is expected to treat approximately 45 adult patients with four or more non-facial SK lesions. They predict the study to be completed by the end of 2017.
NewLink Genetics Corporation (NASDAQ: NLNK)
Market Cap: $300.683M, current share price: $10.20
NLNK a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel immuno-oncology product candidates with the aim to improve the lives of patients suffering from cancer. Also this month, they announced the beginning of a clinical collaboration agreement with AstraZeneca. This collaboration will assess the combination of indoximod, NewLink Genetics' small molecule IDO pathway inhibitor, and durvalumab, AstraZeneca's anti-PD-L1 monoclonal antibody. This is focused along with standard of care chemotherapy for patients with metastatic pancreatic cancer.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO)
Market Cap: $572.04M, current share price: $6.34
Like ENDV, INO is taking immunotherapy to the next level in the fight against cancer as and infectious diseases. INO announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific papers. These reviews demonstrated their impact on prostate tumors and in preventing infection from a pneumonia-causing bacteria in preclinical studies.
Vical Incorporated (NASDAQ: VICL)
Market Cap: $28.9M, current share price: $3.28
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches
For Full Legal Disclaimer Click Here
DISCLAIMER: MicroCapSpeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns MicroCapSpeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, MicroCapSpeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns MicroCapSpeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
FN Media Group, LLC
©2017 PR Newswire. All Rights Reserved.